Short description
Oculis is a clinical-stage biopharmaceutical development company focusing on ophthalmic drugs and novel drug delivery.
Description
The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
Last funding
Blurry Noaccess
Sign in for full access
Total funding
$$43214321
Sign in for full access
Location
Reykjavík, Gullbringusysla, Iceland, Europe
Founded on
January 1, 2003
Exited on
March 3, 2023
Went public on
March 3, 2023
Stock symbol
OCS
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$56378 - 90123
Sign in for full access
Investors
Noaccessforu, Noaccessforu, Noaccess, Noaccess, No Way, Cannot Access, Noaccessforu, Nopepepe, Noaccess, No Way, Noaccessforu, Noaccessforu, Blurry Noaccess, Nopepepe
Sign in for full access
Founders
Einar Stefansson, Thorsteinn Loftsson